Glaukos Prices IPO At $18.00/shr

(RTTNews) - Glaukos Corp. announced the pricing of its initial public offering of 6 million shares of its common stock at a price to the public of $18.00 per share. The offering is scheduled to close on June 30, 2015, subject to customary closing conditions.

The underwriters for the offering will also have a 30-day option to purchase up to an additional 900,000 shares of Glaukos common stock at the price to the public, less the underwriting discounts and commissions.

Glaukos's common stock is expected to begin trading on the New York Stock Exchange on June 25, 2015, under the symbol "GKOS."

Glaukos is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world's leading causes of blindness. Glaukos launched iStent Trabecular Micro-Bypass Stent, the industry's first Micro-Invasive Glaucoma Surgery (MIGS) device, in the United States in 2012. The company is based in Laguna Hills, CA.